Trial Profile
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/radiotherapy in patients with advanced cutaneous Tcell lymphoma not previously treated with intravenous chemotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Registrational; Therapeutic Use
- 30 May 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 30 May 2019 This trial has been discontinued in France, according to European Clinical Trials Database.
- 01 Dec 2013 Accrual to date is 27% according to United Kingdom Clinical Research Network.